Product news from the 09/12/06 News Brief

Share this article:
Barr Pharmaceuticals launched a generic version of its extended-cycle oral contraceptive Seasonale under the tradename Jolessa. The company launched this generic version of Seasonale following the final FDA approval of Watson Laboratories’ Abbreviated New Drug Application (ANDA) for a generic version of Seasonale. Watson received approval following the expiration of the Barr’s three-year new product exclusivity on Sept. 5, 2006. King Pharmaceuticals entered into an agreement with Ligand Pharmaceuticals to acquire rights to Avinza (morphine sulfate extended release). Avinza is an extended-release formulation of morphine and is indicated as a once-daily treatment for moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.